GeneDx Holdings (WGS) said Tuesday it is expanding its genetic testing footprint to now add cerebral palsy.
The testing offers information for personalized treatment and management strategies, the company added.
GeneDx's stock was down 1.2% in recent Tuesday trading.
Price: 93.20, Change: -1.15, Percent Change: -1.22